Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Sep-Oct;43(5):606-609.
doi: 10.1016/j.clindermatol.2025.03.006. Epub 2025 Mar 27.

Prurigo Nodularis: A historic perspective

Affiliations

Prurigo Nodularis: A historic perspective

Sarah G Brooks et al. Clin Dermatol. 2025 Sep-Oct.

Abstract

Prurigo nodularis (PN) is a chronic inflammatory skin condition characterized by firm, itchy nodules and relentless itch. PN was first described in the 19th century. After observations of various dermatologists, the clinical presentation was officially given a name in 1909 by James Nevins Hyde. Throughout the 1900s, PN gained pockets of attention concerning its histopathologic features, epidemiology, and pathophysiology, although it existed as a largely ambiguous disease for many years. Only at the turn of the 21st century was the recognition of PN reignited, prompting extensive research and leading to striking advancements in our understanding of the mechanisms that had contributed to PN during the last decade. Despite a long and inconsistent course, there are now definitive immune and neural pathways that can be selectively targeted with novel therapies, suggesting a promising future for managing this debilitating condition.

PubMed Disclaimer

Conflict of interest statement

Declaration of competing interest Dr Yosipovitch receives grants from Sanofi; Regeneron Pharmaceuticals, Inc; Pfizer; Escient; Novartis; Eli Lilly; Celldex; and Kiniksa Pharmaceuticals. Dr Yosipovitch participates on an advisory board for Abbvie; Escient Health; Eli Lilly; Galderna; LEO Pharma; Novartis; Pfizer; Pierre Fabre; Regeneron Pharmaceuticals, Inc; Sanofi; Trevitherapeutics; Vifor; Kamari; and GSK. Dr Yosipovitch receives consulting fees from Abbvie; Arcutis; Escient Health; Eli Lilly; Galderma; LEO Pharma; Novartis; Pfizer; Pierre Fabre; Regeneron Pharmaceuticals, Inc; Sanofi; Trevitherapeutics; Vifor; Kamari; and Kiniksa. He holds a patent for topical acetaminophen. The remainder of the authors have no conflicts of interest to report.

Publication types

LinkOut - more resources